Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00312975
Status:
COMPLETED
Last Update Posted:
2012-06-07
First Post:
2006-04-07
Brief Title:
Randomized Study Of CP-675206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer NSCLC
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Phase 2 Randomized Non-Comparative Study Of CP-675206 Or Best Supportive Care Immediately Following First-Line Platinum-Based Therapy In Patients With Stage IIIB With Effusion Or Stage IV Non-Small Cell Lung Cancer That Has Responded Or Remained Stable
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to study how long patients can remain progression free when they receive CP-675206 compared to how long patients can remain progression free when they receive best supportive care If you choose to take part you will be randomized to receive either CP-675206 as maintenance therapy or best supportive care Best supportive care means you will not receive any study drug or other treatment for your cancer Best supportive care could include treatment with antibiotics analgesic drugs medicine for pain blood transfusions or psychosocial and nutritional support depending on your needs You have a 50 chance of being randomized to receive CP-675206
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None